06
068270.KO Celltrion Inc
- Market cap
- KRW 49.0T
- P/E
- 28.9x
- P/B
- 2.42x
- ROE
- 8.0%
- Dividend yield
- 0.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 068270.KO undervalued?
Graham number068270.KO trades 76.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celltrion Inc fundamental analysis
No fundamental analysis for Celltrion Inc yet.
Celltrion Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic col…
Full company profileCelltrion Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celltrion Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 671B | 949B | 982B | 1.13T | 1.85T | 1.91T | 2.28T | 2.18T | 3.56T | 4.16T | 5.08T |
| Gross Profit | 397B | 698B | 551B | 633B | 1.03T | 1.11T | 1.03T | 1.05T | 1.68T | 2.47T | 3.10T |
| Operating Income | 250B | 500B | 323B | 382B | 719B | 757B | 647B | 651B | 492B | 1.16T | 1.55T |
| EBITDA | 348B | 597B | 444B | 546B | 841B | 999B | 873B | 927B | 1.07T | 1.52T | 2.20T |
| Net Income | 178B | 368B | 246B | 301B | 518B | 579B | 538B | 536B | 423B | 1.03T | 1.43T |
| EPS | 1,229 | 2,536 | 1,686 | 2,074 | 3,560 | 3,982 | 3,888 | 2,584 | 1,964 | 4,706 | 6,247 |
| Balance Sheet | |||||||||||
| Total Assets | 3.02T | 3.29T | 3.50T | 3.86T | 5.02T | 5.67T | 5.89T | 19.9T | 21.1T | 22.3T | 23.7T |
| Total Liabilities | 823B | 884B | 908B | 987B | 1.59T | 1.62T | 1.62T | 2.79T | 3.48T | 4.98T | 5.65T |
| Shareholders' Equity | 2.05T | 2.29T | 2.49T | 2.76T | 3.31T | 3.92T | 4.14T | 17.0T | 17.4T | 17.2T | 17.9T |
| Cash & Short-term Investments | 274B | 558B | 532B | 628B | 698B | 1.22T | 594B | 565B | 996B | 1.12T | 1.08T |
| Total Debt | 679B | 641B | 517B | 495B | 774B | 744B | 792B | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 251B | 486B | 365B | 474B | 351B | 911B | 864M | 537B | 902B | 646B | 1.30T |
| Capital Expenditure | 178B | 97.0B | 188B | 286B | 541B | 322B | 312B | 354B | 334B | 332B | 516B |
| Free Cash Flow | 72.6B | 389B | 177B | 188B | -191B | 590B | -311B | 183B | 568B | 314B | 787B |
| Ratios | |||||||||||
| ROE | 8.7% | 16.1% | 9.9% | 10.9% | 15.7% | 14.8% | 13.0% | 3.2% | 2.4% | 6.0% | 8.0% |
| ROA | 5.9% | 11.2% | 7.0% | 7.8% | 10.3% | 10.2% | 9.1% | 2.7% | 2.0% | 4.6% | 6.0% |
| Net Profit Margin | 26.5% | 38.8% | 25.0% | 26.7% | 28.0% | 30.3% | 23.5% | 24.6% | 11.9% | 24.7% | 28.2% |
| Debt to Equity | 0.33x | 0.28x | 0.21x | 0.18x | 0.23x | 0.19x | 0.19x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Celltrion Inc dividends
- Dividend yield
- 0.31%
- Forward dividend
- 714.29 KRW
- Payout ratio
- 14.9%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 154B | 703 | 14.9% |
| 2024 | KRW 104B | 481 | 24.5% |
| 2023 | KRW 51.7B | 249 | 9.6% |
| 2022 | KRW 102B | 741 | 19.0% |
| 2021 | KRW 3.78M | 0.03 | 0.0% |
| 2020 | KRW 3.78M | 0.03 | 0.0% |
| 2019 | KRW 3.78M | 0.03 | 0.0% |
| 2018 | KRW 3.78M | 0.03 | 0.0% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Jun 4, 2026.
Who owns Celltrion Inc
- Insiders 36.39%
- Institutions 21.59%
- Public & others 42.01%
- Shares outstanding 228M
- Free float 159M
Celltrion Inc company profile
- Company name
- Celltrion Inc
- Ticker
- 068270.KO
- ISIN
- KR7068270008
- Exchange
- Korea Stock Exchange
- Listed since
- Jul 19, 2005
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,956
- Fiscal year end
- December
- Address
- 23, Academy-ro, Incheon, South Korea
- Phone
- 82 3 2850 5000
- Website
- celltrion.com
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Celltrion Inc management
5- Mr. Woo-Sung KeeCo-CEO & Internal Director · born 1961
- Mr. Jin-Seok SeoCo-CEO & Inside Co-Chairman of the Board · born 1984
- Mr. Stephen YeumFounder
- Mr. Min-Cheol ShinCFO, Director of Finance & Inside Director · born 1971
- Mr. Ji-Hoon ChoiDirector of Legal Affairs · born 1971